安非他酮缓释片与帕罗西汀治疗帕金森病抑郁的对照研究

Abstract
Figure/Table
References (17)
Related Citation (15)

Download: PDF (0 KB) HTML (39 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To compare the efficacy of Bupropion Sustained-Release Tablets and Paroxetine in improving depression and quality of life in the patients with Parkinson′s disease.Methods From February 2016 to September 2017,42 patients with Parkinson′s disease complicated with depression who were were admitted to the outpatient and inpatient in Tai′an Psychiatric Hospital were selected.The random number table was used to divide them into study group and control group,21 patients in each group.The study group was given Bupropion Sustained-Release Tablets for treatment,and the control group was given Paroxetine for treatment.The course of treatment was 6 weeks.The degree of depression changes was assessed by the Hamilton Depression Scale(HAMD).The third subscale of the comprehensive Parkinson′s disease rating Scale(UPDRS)was used to assess motor function.39-item Parkinson′s disease questionnaire(PDQ-39)scores were used to assess the changes in quality of life.Results Before treatment,the scores of HAMD,UPDRS,and PDQ-39 in the two groups of patients were compared,and the differences were not statistically significant(P＞0.05).After 2,4,and 6 weeks of treatment,the HAMD scores in both groups were significantly lower than those before treatment,and the differences were statistically significant(P＜0.01).There was no statistically significant difference in HAMD scores between the two groups(P＞0.05);the third subscale of UPDRS and PDQ-39 score in the study group at 2,4 and 6 weeks were significantly lower than those before treatment(P＜0.01).There was no statistically significant difference in the control group compared with that before treatment(P＞0.05).Conclusion Bupropion Sustained-Release Tablets can not only improve the depression of the patients with Parkinson′s disease,but also improve the motor symptoms and quality of life in the patients with Parkinson′s disease and depression,which is worthy of promotion.

Key words： Bupropion Sustained-Release Tablets Depression Dyskinesia Quality of life

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIAN Peng
	SUN Meng-meng
	FENG Lin
	FENG Xiao-li
	ZHANG Can-wen

Cite this article:

LIAN Peng,SUN Meng-meng,FENG Lin, et al. Controlled study on Bupropion Sustained-Release Tablets and Paroxetine in the treatment of depression induced by Parkinson′s disease[J]. 中国当代医药, 2018, 25(13): 147-150.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2018/V25/I13/147

[1]	贾建平.神经病学[M].6版.北京：人民卫生出版社，2008：273-274.
[2]	Slaughter JR，Slaughter KA，Nichols D，et al.Prevalence，clinical manifestations，Etiology，and treatment of depression in Parkinson′s disease[J].J Neuropsychiatry Clin Neurosci，2001，13（2）：187-196.
[3]	孟庆进，柴晓斌，胡国华.帕金森病后抑郁的最新研究进展[J].中国老年学杂志，2013，33 （2）：477-478.
[4]	刘振江，秦玲，徐国良.盐酸安非他酮和盐酸氟西汀治疗抑郁症的有效性及安全性的Meta分析[J].吉林大学学报（医学版），2015，41（1）：140-141.
[5]	中华医学会神经病学分会运动障碍及帕金森病学组.帕金森病的诊断[J].中华神经科杂志，2006，39（6）：408-409.
[6]	汪向东，王希林，马弘.心理卫生评定量表手册增订版[M].北京：中国心理卫生杂志社，1999：220-223.
[7]	Achey MA，Beck CA，Beran DB，et al.Virtual house calls for Parkinson disease（Connnect.Parkinson）：study protocol for a randomized，controlled[J].Trials，2014，15（1）：465-467.
[9]	张雪，张雯，杜立达，等.抗帕金森病药物及其作用靶点研究进展[J].国际药学研究杂志，2016，43（1）：87-88.
[10]	金莺，陈葵，蒋红.中晚期帕金森病患者生活质量调查及分析[J].中国临床神经科学，2017，25 （5）：500-504.
[11]	李金虹，钱进，富欣然，等.帕金森病患者焦虑及抑郁与其他症状关系的研究[J].中国全科医学，2016，19（17）：2002-2005.
[12]	李杨，谢宇宽，邱华艳，等.行为疗法联合普拉克索对早发型帕金森病合并抑郁症患者HAMD评分、Zung评分和UPDRSⅡ、Ⅲ评分的影响[J].中国健康心理学杂志，2018，26（1）：10-12.
[8]	Tsang KL，Chi I，Ho SL，et al.Translation and validation of the standard Chinese version of PDQ-39：a quality-of-life measure for patients with Parkinson′s disease[J].Mov Disord，2002，17（5）：1036-1040.
[13]	Connolly BS，Lang AE.Pharmacological treatment of Parkinson disease：a review[J].JAMA，2014，311（16）：1670-1683.
[14]	白雪，蒋雨平.帕金森病左旋多巴剂峰异动症的治疗[J].中国临床神经科学，2017，25（3）：301-305.
[15]	季晓飞，董惠洁，陈亮.普拉克索单用和联用艾司西酞普兰对改善帕金森病患者抑郁症状及生活质量的比较[J].中国新药与临床杂志，2013，32（1）：59-62.
[16]	王韵，粟幼嵩，张桦.普拉克索治疗双相抑郁障碍的临床应用[J].国际精神病学杂志，2015，42（3）：138-140.
[17]	中华医学会神经病学分会帕金森病及运动障碍学组.中国帕金森病治疗指南（第3版）[J].中华神经科杂志，2014，47（6）：428-433.